Nasdaq · Biotech stocks database
SPRY (ARS Pharmaceuticals Inc.) stock: $2.79, $277.5M market cap, $138.3M cash, $261.0M EV, $331.9M fully diluted market cap. Lead program: Neffy (Allergic Reactions), Phase 4. Data from Fully Diluted's biotech stocks database.
We believe neffy ’s “no needle, no injection” approach addresses a significant unmet need in the use of epinephrine. There are approximately 40 million people in the U.S. who experience Type I allergic reactions. Of this group, approximately 20 million people are reported to have been diagnosed and experienced severe Type I allergic reactions that may lead to anaphylaxis, and approximately 6.5 million of those were prescribed an epinephrine autoinjector.
Source: 10-K FY2025 via SEC EDGAR
| Cash | $138.3M |
|---|---|
| Debt | $121.8M |
| Net cash | $16.5M |
| Enterprise value | $261.0M |
| Basic shares | 100.5M shares |
| Fully diluted shares | 119.0M shares |
| Fully diluted market cap | $331.9M |
| Cash per share | $1.38 |
| Quarterly burn | $60.9M |
| Cash runway | 2.4 quarters |
Cash figures as of 2026-09-30. Database snapshot: 2026-11-07.
Cap table as of 2026-06-30.
Loading SPRY daily closes…
ARS-2 (neffy) · Est. Feb 14, 2027 · quarter midpoint · guided in 8 wks